Sun Pharma extends patient support program for cancer drug in US

Sun Pharma has announced the extension of its Imatinib Mesylate Savings Card Program in the US beyond July 31, 2016. Started as part of the imatinib mesylate launch in February 2016, the program is aimed at delivering greater access to the drug to patients who have commercial insurance, but whose out-of-pocket cost may exceed an affordable amount. Imatinib mesylate is used in the treatment of multiple cancers

As part of the Imatinib Mesylate savings card program extension, Sun Pharma will continue to offer up to $ 700 reduction on each eligible patient’s initial out-of-pocket cost from their commercial insurer thereby reducing the patient’s out-of-pocket co-payment to as low as $ 10. This benefit will cover a patient’s monthly fills for a 30-day supply of Sun Pharma’s Imatinib Mesylate prescribed for Ph+CML, a form of chronic myeloid leukemia through the extension period.